• Users Online: 429
  • Home
  • Print this page
  • Email this page
This article has been cited by
1Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis
Vadim Makarov,Elena Salina,Robert C. Reynolds,Phyo Phyo Kyaw Zin,Sean Ekins
Journal of Medicinal Chemistry.2020;()
2Activity of DNA-targeted C8-linked pyrrolobenzodiazepine–heterocyclic polyamide conjugates against aerobically and hypoxically grown Mycobacterium tuberculosis under acidic and neutral conditions
Angelo Iacobino,Federico Giannoni,Lanfranco Fattorini,Federico Brucoli
The Journal of Antibiotics.2018;71(9)831
3Novel MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis and Synergize with Electron Transport Chain Inhibitors
Bryan J. Berube,Dara Russell,Lina Castro,Seoung-ryoung Choi,Prabagaran Narayanasamy,Tanya Parish
Antimicrobial Agents and Chemotherapy.2019;63(6)831
4Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence
Saif Khan,Raju K. Mandal,Abdulbaset Mohamed Elasbali,Sajad A. Dar,Arshad Jawed,Mohd Wahid,Harishankar Mahto,Mohtashim Lohani,Bhartendu Nath Mishra,Naseem Akhter,Ali A. Rabaan,Shafiul Haque
Bioscience Reports.2019;39(1)831
5Modeling of Mycobacterium tuberculosis dormancy in bacterial cultures
Yana R. Batyrshina,Yakov Sh Schwartz
6The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH
Angelo Iacobino,Federico Giannoni,Manuela Pardini,Giovanni Piccaro,Lanfranco Fattorini
Antimicrobial Agents and Chemotherapy.2019;63(7)7
7Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients
Michael A. Lyons
Antimicrobial Agents and Chemotherapy.2019;63(12)7
8A rapid, low pH, nutrient stress, assay to determine the bactericidal activity of compounds against non-replicating Mycobacterium tuberculosis
Julie V. Early,Steven Mullen,Tanya Parish,Adelaide Almeida
PLOS ONE.2019;14(10)e0222970
9Drug-Resistant Tuberculosis 2020: Where We Stand
Angelo Iacobino,Lanfranco Fattorini,Federico Giannoni
Applied Sciences.2020;10(6)2153
10Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs In Vitro
E. D. Pieterman,M. J. Sarink,C. Sala,S. T. Cole,J. E. M. de Steenwinkel,H. I. Bax
Antimicrobial Agents and Chemotherapy.2020;64(7)2153
11Development and biological evaluation of a new nanotheranostic for tuberculosis
Edward Helal-Neto,Suyene Rocha Pinto,Filipe Leal Portilho,Marcellus Dias da Costa,Jonathas Xavier Pereira,Fiammetta Nigro,Eduardo Ricci-Junior,Andre Luis Peixoto Candéa,Maria das Graças Muller de Oliveira Henri,Ralph Santos-Oliveira
Drug Delivery and Translational Research.2019;9(1)97